Nec Transporter Protein Enhances HMO Efflux in Genetically Modified Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biotechnological methods for producing human milk oligosaccharides (HMOs) face challenges in identifying the right sugar efflux transporter proteins, leading to inefficient production and purification processes due to unpredictable substrate specificity of sugar transporters.
Innovation Solution
Genetically modified cells expressing a putative Major Facilitator Superfamily (MFS) transporter protein from Rosenbergiella nectarea, specifically the Nec protein, are developed to enhance the production and recovery of HMOs by optimizing sugar efflux, reducing by-product formation, and improving cell viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional sugar transporter proteins are used for HMO efflux, then production can proceed, but substrate specificity is unpredictable leading to inefficient production and purification processes
Solution Approach 1:
The patent changes the key parameter of transporter protein identity from conventional, poorly characterized transporters to the specifically identified MFS transporter from Rosenbergiella nectarea. This parameter change provides predictable substrate specificity for HMO efflux while maintaining high productivity, resolving the contradiction between production efficiency and specificity reliability.
2Productivity
If high levels of recombinant gene expression are used to increase HMO production, then productivity improves, but metabolic burden on the producing cell increases
Solution Approach 1:
The MFS transporter protein acts as an intermediary that facilitates efficient HMO efflux from the cell. By improving the rate and efficiency of product export, the transporter reduces intracellular accumulation of HMOs and their precursors, thereby reducing metabolic burden on the cell while maintaining high productivity.
3Productivity
If efficient sugar efflux is achieved to improve HMO recovery, then product recovery improves, but by-product formation may increase
Solution Approach 1:
The patent employs feedback control through the use of a transporter with well-characterized substrate specificity. The MFS transporter's predictable preference for specific HMO structures allows for optimized expression conditions that favor desired product efflux while minimizing conditions that would lead to by-product formation, achieving both high recovery and low by-products.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of Nec protein-expressing cells results in higher HMO yields, reduced biomass formation, and streamlined downstream processing, leading to more efficient and cost-effective HMO manufacturing with improved product recovery and reduced by-product formation.
Implementation Method 1
Genetically modified cells expressing a putative Major Facilitator Superfamily (MFS) transporter protein from Rosenbergiella nectarea, specifically the Nec protein, are developed to enhance the production and recovery of HMOs by optimizing sugar efflux
Data Source
AI summary
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic encoding a putative transporter protein of the MFS superfamily; and methods using said cell for the production of oligosaccharide(s), preferably an HMO.